http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105078983-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate | 2014-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105078983-B |
| titleOfInvention | The purposes of astemizole, its salt or solvate in the drug of preparation prevention and/or treatment malignant lymphoma |
| abstract | The present invention relates to astemizole (Astemizole) shown in formula (Ι), pharmaceutically acceptable salt or solvate are preparing the purposes in prevention and/or the drug for treating malignant lymphoma for it, as (the Polycomb Repressive Complex2 of multi-comb inhibiting compound 2, that is PRC2) inhibitor purposes, and as EZH2-EED interaction inhibitor purposes.The malignant lymphoma is the relevant disease of Germinal center B cell lymthoma.And the pernicious leaching lymthoma includes Hodgkin lymphoma and non-Hodgkin lymphoma.In addition the astemizole, pharmaceutically acceptable salt or solvate can be used in combination with EZH2 inhibitor for it. |
| priorityDate | 2014-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.